Market Overview

JP Morgan Initiates Coverage On Myovant Sciences with Overweight Rating, Announces $39 Price Target


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for MYOV

Sep 2018JP MorganInitiates Coverage OnOverweight
Apr 2018BarclaysDowngradesOverweightEqual-Weight
Aug 2017Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for MYOV
View the Latest Analyst Ratings

Posted-In: News Initiation Analyst Ratings


Related Articles (MYOV)

Pivotal: Snap No Longer A Sell, But Stock Could Still Fall

The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx